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The group of pattern recognition recep-
tors (PRRs) includes families of toll-like
receptors (TLRs), NOD-like receptors
(NLRs), C-type lectin receptors (CLRs),
RIG-I-like receptors (RLRs), and AIM2-
like receptors (ALRs) (1–7). Conceptually,
receptors constituting these families are
united by two general features. Firstly, they
directly recognize common antigen deter-
minants of virtually all classes of pathogens
(so-called pathogen-associated molecular
patterns, PAMPs) and initiate immune
response against them via specific intracel-
lular signaling pathways (1–7). Secondly,
they also recognize endogenous ligands
released in cells under stress, which are
known as damage-associated molecular
patterns (DAMPs). Therefore, a subset of
PRR-mediated immune response can be
activated without an influence of infectious
agents (1–7).
Long-standing data implicate that PRRs
play a key role in innate and adaptive
immune responses (1–7). Besides their
effect on immunity, many PRRs may have
a crucial impact on almost all vital cellu-
lar processes, such as cell growth, survival,
apoptosis, cell cycle control, cell prolifera-
tion and differentiation, autophagy, angio-
genesis, cell motility, and migration (8–14).
In recent years, the evidence of the involve-
ment of PRRs in the processes of DNA
repair started to emerge. A recent com-
prehensive review by Harberts and Gas-
pari (15) has shed light on this issue;
nevertheless, a number of newer investiga-
tions were performed after the publication
of their paper.
One of the most investigated TLRs is
TLR4, which is a transmembrane pro-
tein with an ectodomain located on the
cell surface (16). The two most known
TLR4 ligands are lipopolysaccharide (LPS),
one of the main components of Gram-
negative bacteria outer membrane, and
high-mobility group protein B1 (HMGB1),
which is known to be an important chro-
matin protein (16). It is well known
that X-ray repair cross-complementing
group (XRCC)5/KU80 and XRCC6/KU70
are the key non-homologous end-joining
(NHEJ) repair pathway proteins (17, 18).
Wang et al. observed that a diminish-
ment of TLR4-mediated immune response
may lead to reduced expression of
XRCC5/KU80 and XRCC6/KU70 in mouse
liver tissue and cells in response to
the diethylnitrosamine, therefore, being a
cause of the DNA repair impairment and
reactive oxygen species (ROS) accumula-
tion (17, 18). However, when TLR4−/−
mice and wild-type mice were locally
exposed to ultraviolet B (UVB, shortwave
radiation), the expression of DNA repair
gene xeroderma pigmentosum, comple-
mentation group A (XPA), and produc-
tion of interleukins (ILs) 12 and 23 were
significantly higher (19). Further, cyclobu-
tane pyrimidine dimers were repaired
more efficiently in the skin and bone
marrow-derived dendritic cells (DCs) of
TLR4−/− mice (19). The addition of anti-
IL-12 and anti-IL-23 antibodies to bone
marrow-derived DCs of TLR4−/− mice
before UVB exposure inhibited repair of
cyclobutane pyrimidine dimers along with
a decline of XPA gene expression; simi-
larly, the addition of TLR4 agonist to wild-
type bone marrow-derived DCs lowered
XPA gene expression and diminished repair
of cyclobutane pyrimidine dimers (19).
Hence, the activation of TLR4 signaling by
ultraviolet radiation may launch a specific
pathway and result in decrease of IL-12
and/or IL-23 production, thereby reduc-
ing the expression of genes encoding DNA
repair enzyme such as XPA (19). According
to these studies (17–19), TLR4 may both
upregulate and downregulate distinct DNA
repair proteins, and possibly does it in dif-
ferent ways in distinct cell types, so its exact
role in DNA repair remains unclear.
Certain TLRs are located on the endo-
plasmic reticulum membrane (in a rest-
ing state) or on the endosomal/lysosomal
membrane (upon ligand stimulation and
trafficking) (20). Among these are TLR7,
TLR8, and TLR9 (20). The main ligands
for TLR7 and TLR8 are imidazoquinolines,
ssRNA, and antiphospholipid antibodies,
while the main ligands for TLR9 are bacter-
ial and viral CpG DNA and IgG-chromatin
complexes (20). However, all these recep-
tors signal via the protein encoded by
myeloid differentiation primary response
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gene 88 (MyD88) (20). Tsukamoto et al.
found that 8-mercaptoguanosine (8SGuo)
induces the activation-induced cytidine
deaminase (AID) expression and double-
strand breaks (DSBs) through TLR7–
MyD88-dependent pathway in cluster of
differentiation (CD)38- or B cell recep-
tor (BCR)-activated B cells (21). Nev-
ertheless, imiquimod, a TLR7/8 agonist,
which is used in the treatment of cer-
tain non-melanoma skin cancer, increased
an expression and nuclear localization of
XPA gene and other DNA repair genes
in a MyD88-dependent manner (22). In
addition, as it was detected by Fishelevich
et al. imiquimod enhanced DNA repair
and accelerated the resolution of cyclobu-
tane pyrimidine dimers after an exposure
of bone marrow-derived cells to ultraviolet
light (22). Imiquimod-activated cutaneous
antigen presenting cells were characterized
by better DNA repair in comparison with
resting antigen presenting cells under the
exposure to both non-ionizing and ioniz-
ing radiation (22). Moreover, topical appli-
cation of imiquimod before the exposure to
ultraviolet light had a protective effect and
reduced the number of cyclobutane pyrim-
idine dimers-positive antigen presenting
cells (22). Therefore, the role of TLR7 and
TLR8 in DNA repair may differ depend-
ing on their influence on the specific DNA
repair proteins or on the cell type, as in the
case with TLR4.
In the study of Zheng et al., TLR9-
stimulated CD4 T cells demonstrated
an increased capacity to repair ioniz-
ing radiation-induced DSBs, whereas the
treatment of irradiated CD4 T cells with
TLR9 ligands along with checkpoint kinase
(Chk)1/2 inhibitors or along with ataxia
telangiectasia mutated/ataxia telangiecta-
sia and Rad3 related (ATM/ATR) inhibitor
wortmannin abrogated the improvement
of DNA repair observed previously (23). In
addition, TLR9 stimulation did not elevate
DNA repair rates after an exposure to ion-
izing radiation in TLR9−/− and MyD88−/−
CD4 T cells; thus, TLR9-induced DNA
repair may be mediated by Chk1/2 and
ATM/ATR via MyD88-dependent pathway
(23). Klaschik et al. performed a global
gene expression analysis on mouse splenic
cells and revealed that CpG DNA, a lig-
and for TLR9, may cause the activation
of genes responsible for DNA repair 3–
5 days after an intraperitoneal injection, so
the long-term enhancement of DNA repair
after TLR9 stimulation is possible (24).
Sommariva et al. carried out an in silico
analysis of DNA repair genes in data sets
obtained from murine colon carcinoma
cells in mice injected intratumorally with
synthetic oligodeoxynucleotides express-
ing CpG motifs (CpG–ODN, a TLR9
agonist) and from splenocytes in mice
treated intraperitoneally with CpG–ODN
(25). According to their results, CpG–
ODN downregulated DNA repair genes in
tumors, but upregulated them in immune
cells (25). Moreover, «CpG-like» expres-
sion pattern of CpG–ODN modulated
DNA repair genes was associated with a
better outcome of patients with breast and
ovarian cancer treated by DNA-damaging
agents than «CpG-untreated-like» expres-
sion pattern, so these genes may determine
tumor cell response to genotoxic drugs
(25). It seems to be that the exact role of
TLR9 in DNA repair substantially depends
on the cell type.
It was found that MyD88 mediates the
optimal activation of the Ras/mitogen-
activated protein kinase (MAPK) pathway
by binding to extracellular signal-regulated
kinase (ERK) and protecting it from
dephosphorylation (26–29). In accor-
dance with the data obtained by Kfoury
et al., MyD88 inhibition may lead to defec-
tive excision repair cross-complementing
rodent repair deficiency, complementation
group 1 (ERCC1)-dependent DNA repair
and to accumulation of DNA damage (29,
30). In addition, abrogation of MyD88 gene
expression sensitizes cancer cells to geno-
toxic agents such as platinum salts in vitro
and in vivo (29, 30). It is worthy of note that
platinum-based chemotherapeutic agents
(cisplatin, carboplatin, and oxaliplatin)
cause DNA damage that is preferentially
repaired by the nucleotide excision repair
(NER) pathway, which is implicated in the
repair of DNA single-strand breaks (SSBs),
and ERCC1 predominantly functions as
NER enzyme via Ras-MAPK pathway (29,
30). So, MyD88-dependent Ras-MAPK-
mediated activation of ERCC1 may play a
major role in DNA repair (29, 30). How-
ever, Lai and Egan reported that early
induction of DSBs in mouse colonic
epithelial cells by ionizing radiation was
independent of the presence and absence
of MyD88 gene expression (31). Notwith-
standing, they observed a later loss of DSBs
and an enhanced activation of DSB repair
pathways in MyD88−/− mice compared
to control mice (31). It seems to be that
MyD88 has no specific inhibitory effects
regarding the pathways of DSB repair
since both the NHEJ and homologous
recombination (HR) repair pathways were
over-activated in the absence of MyD88
(31). Possibly, MyD88-mediated signaling
pathway may regulate the repair of SSBs
and DSBs in a distinct way via activation
or inhibition of the proteins specific for
each of pathways responsible for the repair
of SSBs and DSBs.
The only study investigating the role
of NLRs in DNA repair was carried out
by Licandro et al. regarding NLR family,
pyrin domain containing 3 (Nlrp3) gene
(32). The ectodomain of NLRP3 recog-
nizes certain DAMPs that may lead to the
assembly of inflammasome and, hence,
to the development of aseptic inflamma-
tion (33). The authors exposed murine
DCs to monosodium urate, rotenone,
and γ-radiation, and detected a lesser
level of DNA fragmentation in Nlrp3−/−
DCs compared to wild-type DCs (32).
Moreover, Nlrp3−/− DCs experienced
significantly less ROS-mediated DNA dam-
age, and a significantly lower expression
of several genes involved in DSB and base
excision repair (BER) was revealed in
wild-type DCs (32). These genes included
XRCC1, RAD51, 8-oxoguanine–DNA gly-
cosylase 1 (OGG1), breast cancer 1, early
onset (BRCA1), DNA polymerase beta
(POLB), and thymidylate synthase (TYMS)
(32). It was demonstrated that DSB and
BER enzymes responsible for repair of
8-oxoguanine, which is a DNA adduct
formed as a result of oxidation, and there-
fore, is considered a marker of oxidative
stress, were more active in Nlrp3−/− cells
in comparison with wild-type DCs (32).
In addition, Nijmegen breakage syndrome
1 (NBS1), another protein involved in
DNA repair, was highly phosphorylated
in Nlrp3−/− DCs compared with wild-
type DCs, indicating greater efficacy of
DNA repair in the absence of Nlrp3 gene
expression (32).
Taken together, these reports strongly
implicate PRRs, in particular TLRs (TLR4,
TLR7, TLR8, and TLR9) and NLRs
(NLRP3), as major regulators of DNA
repair (Table S1 in Supplementary Mate-
rial). According to the above-mentioned
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FIGURE 1 |The general interplay between the canonicalTLR signaling
pathway, the cytokine-mediated DNA repair feedback loop, and the
growth factors-mediated signaling pathway. There are three main
TLR-mediated pathways of DNA repair. The protein encoded by myeloid
differentiation primary response gene 88 (MyD88) and its downstream
signaling proteins (not shown) may inhibit mitogen-activated protein
kinase phosphatase 3 (MKP3), which hinders phosphorylation of
extracellular signal-regulated kinase (ERK), and therefore, prevents further
signaling via Ras-MAPK pathway. In addition, MyD88 and its downstream
signaling proteins (not shown) along with pERK activate AP-1 transcription
factor, which promotes transcription of certain DNA repair genes. Finally,
IL-12 and IL-23, which enhance DNA repair and whose transcription is also
amplified by MyD88-regulated transcription factors, bind to their
receptors, activate Janus kinase-signal transducer and activator of
transcription (JAK-STAT) signaling pathway, and increase further
transcription of their own encoding genes.
findings, these five receptors may affect
the expression of at least eight enzymes
(XRCC1, XRCC5, XRCC6, XPA, BRCA1,
POLB, TYMS, OGG1, and RAD51) and
two ILs (IL-12 and IL-23) involved in
various mechanisms of DNA repair. Fur-
ther, PRRs are responsible not only for
the initiation of one specific DNA repair
pathway, but a number of such pathways
repairing different types of DNA dam-
age, i.e., oxidation, alkylation, and hydrol-
ysis of bases, bulky adducts, SSBs, DSBs,
and crosslinks. Interestingly, the effect of
PRRs on DNA repair may vary between cell
types and cell lines, which address a num-
ber of questions to be answered in future
studies.
Nowadays, we are only beginning to
put the pieces of this puzzle together.
Current vision of this topic is blurred,
although a preliminary picture based on
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recent research can be drawn (Figure 1).
Both TLRs located on the cell surface and
thus responsible for the recognition of
the pathogen envelope molecular patterns
(TLR4) and TLRs located on the endoplas-
mic reticulum, endosomal, or lysosomal
membrane, and therefore, responsible for
the recognition of pathogen nucleic acids
(TLR7, TLR8, and TLR9) are involved
in DNA repair. Therefore, other TLRs
belonging to any of these groups may
also participate in such processes. Defi-
nitely, the cytokine-mediated DNA repair
feedback loop is not restricted to IL-12
and IL-23, and might consist of much
greater number of cytokines, possibly TLR-
regulated cytokines [IL-1, IL-2, IL-6, IL-8,
IL-10, IL-13, IL-27, macrophage inflam-
matory protein-1 (MIP-1), monocyte
chemotactic protein-1 (MCP-1), regulated
on activation, normal T-cell expressed
and secreted (RANTES), suppressor of
cytokine signaling (SOCS), granulocyte-
macrophage colony-stimulating factor
(GM-CSF), tumor necrosis factor-α (TNF-
α), interferon (IFN)-α, IFN-β, IFN-γ, and
IFN-inducible proteins]. Furthermore,
the exact composition of the growth
factors-mediated DNA repair signaling
pathway is still elusive; importantly, this
pathway may have a particular impor-
tance since it includes both MyD88 and
Ras-MAPK pathways, representing an
interesting example of a crosstalk between
canonical TLR MyD88-mediated signal-
ing pathway and Ras-MAPK signaling
pathway. In addition, there are no studies
on the feasible influence of CLRs, RLRs,
and ALRs on DNA repair. The improve-
ment of our understanding of the role of
PRRs in DNA repair may find implica-
tions for clinical medicine; peculiarities
of PRRs functioning should definitely be
considered when assessing the possibil-
ity of the use of PRR agonists in therapy
of various diseases such as cancer. No
doubt, further in-depth investigations
are needed for deciphering the role of
PRRs in sophisticated mechanisms of DNA
repair.
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